CSL Behring
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-36
RECRUITING9
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO25%
Delay Index: of 8 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.5 months). See all sponsors →
Open CSL Behring on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| BE1116 NCT07094087 |
P3 | Recruiting | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | 200 | 2027-04-06 (-2 mo) |
| CSL511 Fibrinogen concentrate (human) NCT06617897 |
P3 | Recruiting | Acquired Fibrinogen Deficiency | 90 | 2027-06-30 (+10 mo) |
| CSL889 NCT06699849 |
P2 | Recruiting | Sickle Cell Disease Vaso-occlusive Crisis | 70 | 2027-10-22 (-5 mo) |
| Vamifeport NCT07332091 |
P2 | Active, not recruiting | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | 84 | 2028-04-15 |
| Anumigilimab NCT07224360 |
P2 | Recruiting | Sickle Cell Disease | 63 | 2028-08-15 (+2 mo) |
| CSL222 (AAV5-hFIXco-Padua) NCT06003387 |
P3 | Recruiting | Hemophilia B | 35 | 2028-10-04 |
| CSL787 NCT07048262 |
P2 | Recruiting | Non-cystic Fibrosis Bronchiectasis | 180 | 2029-05-06 (+14 mo) |
| POSIBIL6ESKD NCT05485961 |
P2/3 | Recruiting | End Stage Kidney Disease | 3110 | 2029-05-22 (+6 mo) |
| IgPro20 NCT07648264 |
P3 | Recruiting | Secondary Immune Deficiency | 63 | 2029-09-27 |
| IX-TEND 3004 NCT07080905 |
P3 | Recruiting | Hemophilia B | 20 | 2033-10-24 |